A Multicenter, Open-label, Single-arm, Extension Study With Regard to the Safety and Efficacy of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance (EMPIRE-02)
Latest Information Update: 05 Jun 2023
At a glance
- Drugs Empagliflozin (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions
- Acronyms EMPIRE-02
- 02 Jun 2021 Planned End Date changed from 30 Sep 2021 to 31 May 2022.
- 02 Jun 2021 Planned primary completion date changed from 31 Aug 2021 to 1 Feb 2022.
- 02 Jun 2021 Status changed from recruiting to active, no longer recruiting.